Abstract: Provided herein are methods of treating cancer using a combination of (a) one or more programmed death 1 protein (PD-1) antagonists, (b) a radiotherapy, (c) one or more poly (ADP-ribose) polymerase (PARP) inhibitor, and optionally, (d) one or more chemotherapies. Also provided herein is a kit for pharmaceutical administration comprising: (a) a PD-1 antagonist; (b) a radiotherapy; (c) a PARP inhibitor; and (d) optionally, a chemotherapy. Further provided herein are uses of a combination for treating cancer in a human patient, wherein the combination comprises: (a) an effective amount of one or more PD-1 antagonists, (b) an effective amount of a radiotherapy, (c) an effective amount of a PARP inhibitor, and (d) optionally, one or more chemotherapies.

Abstract: Coumermycin analogs of general formula I: wherein X, a linking group, is selected from the group consisting of alkyl, aryl, diaryl, substituted alkyl, substituted aryl, alkyl with hereroatoms in the chain, heteroaryl, cyclic and bicyclic alkyl, and a combination of alkyl, aryl and heteroaryl substituents. The compounds are suitable for use as chemical dimerizers of chimeric proteins.

Abstract: Coumermycin analogs of general formula I: 1

Abstract: An in vivo assay for selecting a candidate therapeutic for treating osteoporosis. A candidate reagent is administered to an IL-4 transgenic mammal whose cells contain a recombinant IL-4 coding sequence operably lined to a promoter sequence which is transcriptionally active in bone marrow cells. At the time the candidate reagent is first administered the IL-4 transgenic mammal is either symptomatic of, or asymptomatic of, an osteoporotic phenotype. The candidate reagent is selected as a candidate therapeutic for treating osteoporosis if either amelioration of, or delay in the onset of, the osteoporotic phenotype is observed following administration of the candidate reagent to the IL-4 transgenic mammal.